Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: An estimate of the treatment cost, $13/month was obtained from the Cystic Fibrosis Foundation The absolute benefit, 41% of those using the treatment avoided complications, is compared with the 16% of those not using the salt water treatment. The treatment was noted as having potentially limited benefit because the prospect of adding an additional 30 minutes of treatment to an already extensive treatment regimen could be a burden. No mention was made of the small (5%) number of patients using the treatment that experienced adverse events. The article describing the two studies failed to detail the nature of the studies. They were two randomized clinical trials. The article explains that cystic fibrosis is a genetic disease and a rare disorder. The reporter contacted a clinician from a cystic fibrosis center that did not appear to have ties to either study. She also included commentsfrom an editorial on the two studies. The advantage of this treatment is that it may reduce the incidence of some serious complications of the disease. The article is clear that this treatment does not cure cystic fibrosis and is used in addition to other therapies, not instead of them. The treatment is available at the centers actually involved in the studies; comments from a third clinician directing treatment of individuals with cystic fibrosis but not involved in the studies indicates that use of this treatment has already been picked up by other groups specializing in cystic fibrosis care. While this could suggest that other groups specializing in cystic fibrosis care might also be offering this treatment, the actual availability is not clear. This article reports on the use of a novel adjunct treatment in the management of cystic fibrosis
Example Output: Saltwater therapy helps ease cystic fibrosis

Example Input: The Centers for Disease Control and Prevention on Wednesday posted data showing nearly 68,000 drug overdose deaths were reported last year. The number may go up as more investigations are completed, but the agency expects the tally will end up below 69,000. Overdose deaths had been climbing each year since 1990, topping 70,000 in 2017. The numbers were celebrated by the U.S. secretary of health and human services. “Lives are being saved, and we’re beginning to win the fight against this crisis,” Alex Azar wrote in a tweet. But the overdose death rate is still about seven times higher than it was a generation ago. “We’re still in a pretty sad situation that we need to address,” said Rebecca Haffajee, a University of Michigan researcher. Researchers do not believe this is the start of a dramatic decline. Data from the first months of this year likely will show that the decrease is not gaining steam, said Farida Ahmad of the CDC’s National Center for Health Statistics. The improvement was driven by a drop in deaths from heroin and prescription painkillers. Those falls were offset somewhat by continuing growth in deaths involving a different opioid, fentanyl, as well as other drugs such cocaine and methamphetamines. Overdose deaths often involve more than one drug. The improvement is not uniform: Some states seem to be making dramatic progress, while deaths continue to rise in others. The preliminary CDC data suggested deaths last year were down by as many as 1,000 or more in Ohio and Pennsylvania — each seeing declines of about 20%. Meanwhile, deaths increased by about 17% in Missouri, which had more than 200 additional deaths. It can take months for authorities to complete toxicology tests and other elements of a death investigation involving drugs. And some states report faster than others. The CDC is expected to report more complete data later this year. The current overdose epidemic has killed more people than any other in U.S. history, and it had been on a soaring trajectory. From 2014 to 2017, overdose deaths jumped by 5,000 or more each year. Experts trace the epidemic’s origins to 1995 and the marketing of the prescription painkiller OxyContin. It was meant be safer and more effective than other prescription opioids, but some patients got hooked and found they could crush the tablets and snort or inject them to get high. Gradually, many turned to cheaper street drugs such as heroin and fentanyl. In 2015, heroin began causing more deaths than prescription painkillers or other drugs. In 2016, fentanyl and its close cousins became the biggest drug killer, and in 2018 they were involved in about 46% of the reported overdose deaths, according to the preliminary CDC data. Strategies to reduce drug overdose deaths have included tougher policing, treatment program expansions, policies to limit opioid painkiller prescriptions and wider distribution of the overdose-reversing drug naloxone. Haffajee and other researchers are trying to figure out what measures are most responsible for the slight improvement. “It’s complicated because there are so many policies going on, and as an evaluator it’s very hard to separate them out and determine which is working,” she said. Valerie Hardcastle, a Northern Kentucky University administrator who oversees research and other work on local health issues, has seen the overdose epidemic play out in her region, near Cincinnati. She believes a major factor is Narcan, a nasal spray version of naloxone, that has been widely distributed through the efforts of philanthropists and local, state, and federal officials. “It’s fantastic that we have fewer deaths, don’t get me wrong,” she said. “But I’m not sure it’s an indication that the opioid problem per se is diminishing. It’s just that we have greater availability of the drugs that will keep us alive.” ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. ___ This story has been corrected to show Ahmad’s first name is Farida, not Farid.
Example Output: Number of US overdose deaths appears to be falling.

Example Input: Cancer patients given a moderate dose of psilocybin — a hallucinogen with effects similar to LSD — were measurably less depressed six months after a single dose compared with a placebo. Patients seemed somewhat less anxious, they reported in the Archives of General Psychiatry. The pilot study of 12 cancer patients was designed to prove that hallucinogenic drugs could be studied safely as a way to relieve the distress of advanced cancer. It revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens. Researchers said the studies were abandoned in the early 1970s when  hallucinogenic drugs such as LSD — lysergic acid diethylamide — became widely used on the streets, leading to strict federal laws regulating their use. “Forty to 45 years ago, the culture was going through tremendous upheaval. These compounds were associated with a very politically active counterculture,” said Dr. Charles Grob of Harbor-University of California Los Angeles Medical Center and the Los Angeles Biomedical Research Institute. “It was something of a public health crisis. Everything had to be shut down,” Grob said in a telephone interview. Federal law prohibits the use of the magic mushroom compound for any purpose. If it proves effective among late-stage cancer patients, U.S. regulators would need to make special accommodation for its use, Grob said. Grob’s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients. During the treatment phase of the study, patients were given a moderate dose of psilocybin and watched closely for six hours. They were told to lie still with their eyes closed as they wore headphones and listened to soothing music. During the placebo phase, each of the 12 patients received a dose of niacin — a vitamin that raises levels of good cholesterol — and given the same instructions. The treatments were given in random order and neither the doctors nor the patients were told which compound was administered. All the volunteers tolerated the treatment sessions well, with no signs of severe anxiety or a “bad trip.” Most patients showed a trend of improvement in their symptoms of anxiety and at six months, and there was a statistically significant improvement on one depression scale. Grob said the pilot study proved the drug could be studied safely in cancer patients. He said two other academic research institutions in the United States — Johns Hopkins University in Baltimore and New York University — were doing similar studies using a slightly higher dose. “Times have changed and it’s now possible to pick up this research model again,” he said. As many as 14 U.S. states and the District of Columbia allow the use of marijuana for medical purposes, and California voters in November will vote on whether to legalize pot. “I think that is an indication that there has been a very strong shift within society to move away from the old cultural bias and politics of the process many years ago. I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,” Grob said.
Example Output:
Magic mushrooms may ease anxiety of cancer: study.